The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
Open accessAbstract
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoietic stem cell transplant. To overcome the cost and transgene-capacity limitations of traditional viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic modification. Following CAR T-cell infusion, 1 patient developed a gradually enlarging retroperitoneal tumor due to a CAR-expressing CD4+ T-cell lymphoma. Screening of other patients led to the detection, in an asymptomatic patient, of a second CAR T-cell tumor in thoracic para-aortic lymph nodes. Analysis of the first lymphoma showed a high transgene copy number, but no insertion into typical oncogenes. There were also structural changes such as altered genomic copy number and point mutations unrelated to the insertion sites. Transcriptome analysis showed transgene promoter–driven upregulation of transcription of surrounding regions despite insulator sequences surrounding the transgene. However, marked global changes in transcription predominantly correlated with gene copy number rather than insertion sites. In both patients, the CAR T-cell–derived lymphoma progressed and 1 patient died. We describe the first 2 cases of malignant lymphoma derived from CAR gene–modified T cells. Although CAR T cells have an enviable record of safety to date, our results emphasize the need for caution and regular follow-up of CAR T recipients, especially when novel methods of gene transfer are used to create genetically modified immune therapies. This trial was registered at www.anzctr.org.au as ACTRN12617001579381.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, in a recent phase I trial, lymphoma arising from piggyBac transfected CAR T cells has been reported in two of nine patients with relapsed or refractory B-cell malignancies who achieved complete remission after product infusion.”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [108]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citationDisruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Structural variant calling: the long and the short of it
Mahmoud, M., Gobet, N., Cruz-Dávalos, D. I., Mounier, N., Dessimoz, C., & Sedlazeck, F. J. (2019) · Genome Biology · doi:10.1186/s13059-019-1828-7 · Cited by 725
Self-citationBishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177
Self-citation
Research works printed but not linked: 62
- Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
- Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science., 302, 415, 10.1126/science.1088547 · DOI · Paper page
- Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J Clin Invest., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
- Shah, 2019, Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy, Blood Adv., 3, 2317, 10.1182/bloodadvances.2019000219 · DOI
- Newrzela, 2011, Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes, Mol Med., 17, 1223, 10.2119/molmed.2010.00193 · DOI
- Kebriaei, 2016, Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J Clin Invest., 126, 3363, 10.1172/JCI86721 · DOI
- Manuri, 2010, piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies, Hum Gene Ther., 21, 427, 10.1089/hum.2009.114 · DOI
- Morita, 2017, Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells, Mol Ther Methods Clin Dev., 8, 131, 10.1016/j.omtm.2017.12.003 · DOI
- Saha, 2012, piggyBac transposon system modification of primary human T cells, J Vis Exp., e4235
- Ramanayake, 2015, Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials, Cytotherapy., 17, 1251, 10.1016/j.jcyt.2015.05.013 · DOI
- Bishop, 2018, PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts, Mol Ther., 26, 1883, 10.1016/j.ymthe.2018.05.007 · DOI
- Singh, 2013, Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells, PLoS One., 8, e64138, 10.1371/journal.pone.0064138 · DOI
- Ryland, 2018, Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing, J Clin Pathol., 71, 895, 10.1136/jclinpath-2018-205195 · DOI
- Markham, 2019, CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing, Sci Rep., 9, 6426, 10.1038/s41598-019-42858-8 · DOI
- Brady, 2011, A method to sequence and quantify DNA integration for monitoring outcome in gene therapy, Nucleic Acids Res., 39, e72, 10.1093/nar/gkr140 · DOI
- Kamboj, 2017, Ub-ISAP: a streamlined UNIX pipeline for mining unique viral vector integration sites from next generation sequencing data, BMC Bioinformatics., 18, 305, 10.1186/s12859-017-1719-4 · DOI
- Freed, The Sentieon Genomics Tools - a fast and accurate solution to variant calling from next-generation sequence data, 10.1101/115717 · DOI
- Jeffares, 2017, Transient structural variations have strong effects on quantitative traits and reproductive isolation in fission yeast, Nat Commun., 8, 14061, 10.1038/ncomms14061 · DOI
- Dennenmoser, 2019, Genome-wide patterns of transposon proliferation in an evolutionary young hybrid fish, Mol Ecol., 28, 1491, 10.1111/mec.14969 · DOI
- Rausch, 2012, DELLY: structural variant discovery by integrated paired-end and split-read analysis, Bioinformatics., 28, i333, 10.1093/bioinformatics/bts378 · DOI
- Layer, 2014, LUMPY: a probabilistic framework for structural variant discovery, Genome Biol., 15, R84, 10.1186/gb-2014-15-6-r84 · DOI
- Chen, 2016, Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications, Bioinformatics., 32, 1220, 10.1093/bioinformatics/btv710 · DOI
- Heinz, 2010, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities, Mol Cell., 38, 576, 10.1016/j.molcel.2010.05.004 · DOI · Paper page
- Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics., 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
- Robinson, 2011, Integrative genomics viewer, Nat Biotechnol., 29, 24, 10.1038/nbt.1754 · DOI · Paper page
- Lawrence, 2013, Software for computing and annotating genomic ranges, PLOS Comput Biol., 9, e1003118, 10.1371/journal.pcbi.1003118 · DOI
- Lawrence, 2009, rtracklayer: an R package for interfacing with genome browsers, Bioinformatics., 25, 1841, 10.1093/bioinformatics/btp328 · DOI
- Yu, 2012, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS., 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
- Shugay, 2018, VDJdb: a curated database of T-cell receptor sequences with known antigen specificity, Nucleic Acids Res., 46, D419, 10.1093/nar/gkx760 · DOI
- Salter, 2018, Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function, Sci Signal., 11, eaat6753, 10.1126/scisignal.aat6753 · DOI
- Tate, 2019, COSMIC: the Catalogue Of Somatic Mutations In Cancer, Nucleic Acids Res., 47, D941, 10.1093/nar/gky1015 · DOI · Paper page
- Galvan, 2009, Genome-wide mapping of PiggyBac transposon integrations in primary human T cells, J Immunother., 32, 837, 10.1097/CJI.0b013e3181b2914c · DOI
- Hamada, 2018, Integration mapping of piggyBac-mediated CD19 chimeric antigen receptor T cells analyzed by novel tagmentation-assisted PCR, EBioMedicine., 34, 18, 10.1016/j.ebiom.2018.07.008 · DOI
- Li, 2013, A resurrected mammalian hAT transposable element and a closely related insect element are highly active in human cell culture, Proc Natl Acad Sci USA., 110, E478, 10.1073/pnas.1121543109 · DOI
- Aganezov, 2020, Comprehensive analysis of structural variants in breast cancer genomes using single-molecule sequencing, Genome Res., 30, 1258, 10.1101/gr.260497.119 · DOI
- Sedlazeck, 2018, Accurate detection of complex structural variations using single-molecule sequencing, Nat Methods., 15, 461, 10.1038/s41592-018-0001-7 · DOI
- Chung, 1997, Characterization of the chicken beta-globin insulator, Proc Natl Acad Sci USA., 94, 575, 10.1073/pnas.94.2.575 · DOI
- Sugie, 2004, Activation of naïve CD4 T cells by anti-CD3 reveals an important role for Fyn in Lck-mediated signaling, Proc Natl Acad Sci USA., 101, 14859, 10.1073/pnas.0406168101 · DOI
- Kataoka, 2015, Integrated molecular analysis of adult T cell leukemia/lymphoma, Nat Genet., 47, 1304, 10.1038/ng.3415 · DOI
- Muragaki, 1991, The complete primary structure of the human alpha 1 (VIII) chain and assignment of its gene (COL8A1) to chromosome 3, Eur J Biochem., 197, 615, 10.1111/j.1432-1033.1991.tb15951.x · DOI
- Liu, 2018, Identification of potential key genes associated with the pathogenesis and prognosis of gastric cancer based on integrated bioinformatics analysis, Front Genet., 9, 265, 10.3389/fgene.2018.00265 · DOI
- Patsoukis, 2020, Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation, Commun Biol., 3, 128, 10.1038/s42003-020-0845-0 · DOI · Paper page
- Richer, 2016, T cell fates zipped up: how the Bach2 basic leucine zipper transcriptional repressor directs T cell differentiation and function, J Immunol., 197, 1009, 10.4049/jimmunol.1600847 · DOI
- Sakane-Ishikawa, 2005, Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group, J Clin Oncol., 23, 8012, 10.1200/JCO.2005.02.1626 · DOI
- Ichikawa, 2014, Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma, Cancer Sci., 105, 437, 10.1111/cas.12361 · DOI
- Liu, 2009, Identification of novel Bach2 transcripts and protein isoforms through tagging analysis of retroviral integrations in B-cell lymphomas, BMC Mol Biol., 10, 2, 10.1186/1471-2199-10-2 · DOI
- Ikeda, 2007, Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy, J Infect Dis., 195, 716, 10.1086/510915 · DOI
- Cesana, 2017, HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells, Nat Commun., 8, 498, 10.1038/s41467-017-00609-1 · DOI
- Newrzela, 2012, T-cell receptor diversity prevents T-cell lymphoma development, Leukemia., 26, 2499, 10.1038/leu.2012.142 · DOI
- Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci Transl Med., 4, 132ra53, 10.1126/scitranslmed.3003761 · DOI
- Recchia, 2006, Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells, Proc Natl Acad Sci USA., 103, 1457, 10.1073/pnas.0507496103 · DOI
- Sheih, 2020, Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy, Nat Commun., 11, 219, 10.1038/s41467-019-13880-1 · DOI
- Nakazawa, 2013, Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes, J Immunother., 36, 3, 10.1097/CJI.0b013e3182791234 · DOI
- Nakazawa, 2011, PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor, Mol Ther., 19, 2133, 10.1038/mt.2011.131 · DOI
- Saito, 2014, Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, Cytotherapy., 16, 1257, 10.1016/j.jcyt.2014.05.022 · DOI
- Gregory, 2018, Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM), Blood., 132, 1012, 10.1182/blood-2018-99-111419 · DOI
- Costello, 2019, Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME), Blood., 134, 3184, 10.1182/blood-2019-129562 · DOI
- Ramezani, 2003, Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator, Blood., 101, 4717, 10.1182/blood-2002-09-2991 · DOI
- Arumugam, 2009, Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region, Mol Ther., 17, 1929, 10.1038/mt.2009.183 · DOI
- Grosso, 2015, Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma, eLife., 4, e09214, 10.7554/eLife.09214 · DOI · Paper page
- Ambrosini, 2018, PWMScan: a fast tool for scanning entire genomes with a position-specific weight matrix, Bioinformatics., 34, 2483, 10.1093/bioinformatics/bty127 · DOI
- Gu, 2014, circlize implements and enhances circular visualization in R, Bioinformatics., 30, 2811, 10.1093/bioinformatics/btu393 · DOI
Cited by
Sorted by citations
Items 101–200 of 204
Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors
Khodabandehloo, E., Rayati, M., Ahmadi, E., Naghdibadi, M., Moradi, V., & Ahmadbeigi, N. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00398-x · Cited by 13
“Although the underlying cause of these two cases could not be fully elucidated, the authors stated that a high transgene copy number per cell is the most likely reason, as one of the patients had 24 transgene copies per cell [92].”
Kozani, P. S., & Kozani, P. S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07183-x · Cited by 13
“Transcriptional dysregulation was associated with these genomic alterations [77, 78].”
Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer
Sueangoen, N., & Prasongtanakij, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01820-x · Cited by 14
“The use of the PB system in clinical trials has gained momentum, partly because of preclinical data confirming its safety and efficacy [60–63].”
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer
Du, W., Noyan, F., McCallion, O., Drosdek, V., Kath, J., Glaser, V., Fuster-García, C., Yang, M.-X., Stein, M., Franke, C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.045 · Cited by 12
“Furthermore, the two recent cases of CAR-derived lymphoma in a trial using hyperactive PiggyBac-modi fi ed T cells 22,23 attest a potential risk of mutagenesis when using transpo-sase technology, which may be attributed to random insertion of multiple transgene copies, genetic dysregulation by…”
Díez, B., Calviño, C., Fernández-García, M., Rodriguez-Marquez, P., Rodríguez-Díaz, S., Martínez-Turillas, R., Ceballos, C., Illarramendi, J., Serrano-López, J., Miskey, C., et al. (2025) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2025.101425 · Cited by 12
“However, recent studies have reported serious adverse effects in two patients treated with CAR-T cell-generated with PB-based systems, 11 – 13 probably due genotoxic events related to the integration pro fi le, similar to the ones described for RVs. 17 18 – 21 This safer pro fi le, together with the…”
RNA-loaded nanoparticles for the treatment of hematological cancers
Garbayo, E., Moukhtari, S. H. E., Rodríguez‐Nogales, C., Agirre, X., Rodríguez-Madoz, J. R., Rodríguez-Márquez, P., Prósper, F., Couvreur, P., & Blanco‐Prieto, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115448 · Cited by 19
Colina, A. S., Shah, V., Shah, R. K., Kozlik, T., Dash, R. K., Terhune, S. S., & Zamora, A. E. (2024) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2024.1310002 · Cited by 12
Lemmens, M., Dorsheimer, L., Zeller, A., & Dietz, Y. (2024) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2024.503767 · Cited by 15
Hadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 14
Fine tuning towards the next generation of engineered T cells
Nguyen, T. T., Ho, P., Staudt, S., Grégoire, C., Ziegler-Martin, K., Jassin, M., Block, A., Hudecek, M., Melenhorst, J. J., Caers, J., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01492-8 · Cited by 11
“Large-scale data show no T cell malignancies in over 3,000 CAR T cell infusions, but low rates of secondary cancers and the increasing use of CRISPR have intensified safety discussions 182–186 .”
DNA transposon mechanisms and pathways of genotoxicity
Bushman, F. D. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.023 · Cited by 12
Are we there yet? The road to faster and more efficient CAR T cell manufacturing
Matos, L. N., Costa, M. S., Serra, M., & Costa, M. H. G. (2026) · Journal of Biological Engineering · doi:10.1186/s13036-026-00666-5 · Cited by 11
“…above 50% have been reported [142], similarly to viral transduction methods, there are risks associated with insertional mutagenesis and CAR T cell lymphoma has been reported when piggyBac-modified CAR T cells were infused [143, 144], which underscores the importance of long-term monitoring.”
Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies
Burón, M., Etxebarria, A., Álvarez, M., Romayor, I., & Eguizábal, C. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2563099 · Cited by 10
“104,105 Finally, Tol2 was the first vertebrate transposable element discovered in medaka fish and it has been extensively used to generate transgenic animals, especially in zebrafish model.”
Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy
Wolter, T., Wang, Y., & Hu, Q. (2024) · BMEMat · doi:10.1002/bmm2.12109 · Cited by 11
Shu, R., Hammett, M., Evtimov, V., Pupovac, A., Nguyen, N.-Y. N., Islam, R., Zhuang, J., Lee, S., Kang, T., Lee, K.-J., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10571 · Cited by 9
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
Wang, V., Savoldo, B., Guimaraes, J.-A., Dotti, G., Reppel, L., & Bensoussan, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1527648 · Cited by 8
CAR assembly line: Taking CAR T-cell manufacturing to the next level
Wang, J., & Caimi, P. F. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101595 · Cited by 10
Klapwijk, J. C., Río-Espínola, A. D., Libertini, S., Collin, P., Fellows, M. D., Jobling, S., Lynch, A. M., Martus, H., Vickers, C. A., Zeller, A., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.033 · Cited by 9
Self-citationTargeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 11
Transposable element DNA and RNA: Drivers of gene expression, evolution, and disease
Ho, J., Douse, C. H., & Marazzi, I. (2026) · Cell · doi:10.1016/j.cell.2026.05.003 · Cited by 8
Ali, A. M., Özdemirli, M., Hamilton, M. P., & Jain, M. D. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01147-w · Cited by 7
“Furthermore, events involving non-integrating delivery systems suggest that genomic instability, rather than integration per se, underlies occasional dysregulated expansions 18 .”
InfluentialChang, P. S., Chen, Y., Hua, W., Hsu, J. C., Tsai, J.-C., Huang, Y.-W., Kao, Y.-H., Wu, P.-H., Wang, P., Chang, Y.-F., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309245 · Cited by 10
Antibiotic-Free Gene Vectors: A 25-Year Journey to Clinical Trials
Marie, C., & Scherman, D. (2024) · Genes · doi:10.3390/genes15030261 · Cited by 9
“No correlation between T-cell lymphoma and the use of the PB transposon has been established [147,148].”
BackgroundAdvances in transposable elements: from mechanisms to applications in mammalian genomics
Han, M., Perkins, M. H., Novaes, L. S., Xu, T., & Chang, H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1290146 · Cited by 9
“These included widespread gains in oncogenes and losses in tumor-suppressor genes, all attributed to uncontrolled random insertions (Micklethwaite et al., 2021).”
BackgroundAmberger, M., Grueso, E., & Ivics, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129799 · Cited by 7
“As this integration step typically occurs in a non-specific and non-targeted manner, it is accompanied by the possibility of unintentionally disrupting, upregulating or downregulating gene expression patterns, potentially leading to detrimental effects including the risk of causing malignant transformation, as demonst…”
BackgroundLin, C., Horwitz, M. E., & Rein, L. A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010204 · Cited by 8
“While recent experience with piggybac transposon-edited CAR-T therapies have led to concerns of the development of CAR T-cell lymphomas, insertional mutagenesis has not been demonstrated in follow-up studies [121,122].”
Ormhøj, M., Abken, H., & Hadrup, S. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03163-y · Cited by 9
Jain, M. D., & Spiegel, J. Y. (2021) · eJHaem · doi:10.1002/jha2.357 · Cited by 10
Expect the unexpected: piggyBac and lymphoma.
Wilson, M. H., & Gottschalk, S. (2021) · Blood · doi:10.1182/blood.2021012349 · Cited by 7
Hickman, A. B., Lannes, L., Furman, C. M., Hong, C., Franklin, L., Ghirlando, R., Ghosh, A., Luo, W., Κωνσταντινίδου, Π., Lorenzi, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55784-9 · Cited by 7
“Futurestudieswilltellwhether piggyBat displaysgenome-wide integration pro fi les that have been a limitation of piggyBac applications due to safety concerns 39 .”
Natural killer cell therapy: the key to tackle the bottleneck of cell therapies against solid tumor?
Wu, D.-W., Miao, H.-L., Ma, X.-X., McCormack, M. P., Huang, H.-Y., Liu, X., & Li, N. (2025) · Science Bulletin · doi:10.1016/j.scib.2024.12.049 · Cited by 6
Current progress in CAR-based therapy for kidney disease
Zhang, D., & Sun, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408718 · Cited by 5
Characterizing piggyBat—a transposase for genetic modification of T cells
Sutrave, G., Xu, N., Tang, T. C. Y., Dolnikov, A., Gloss, B., Gottlieb, D., Micklethwaite, K., & Gowrishankar, K. (2022) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.012 · Cited by 6
Self-citationDong, J., Nikolenko, D. A., Boymuradov, S., Garifulina, L., & Khodabandehloo, E. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04185-5 · Cited by 6
“For example, in 2021, Micklethwaite reported two cases of CAR-T cell-derived leukemia in patients who had received CD19 CAR-T cells produced by PiggyBac transposon vector [46].”
Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy
Tatetsu, H., Kato, K., Wada, A., Hirano, T., Ueno, S., Miyasato, Y., Yamada, A., Shichijo, T., Higuchi, Y., Ueda, Y., et al. (2025) · International journal of hematology · doi:10.1007/s12185-025-04074-1 · Cited by 5
“T cell lymphoma was previously reported in two patients in a phase I trial using piggyBac transposons for non-viral CD19 CAR T cell therapy [7, 8].”
Navigating CAR-T cell therapy long-term complications
Grégoire, C., & Melenhorst, J. (2024) · Nature Cancer · doi:10.1038/s43018-024-00867-1 · Cited by 5
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15
“The pathogenic mechanism for the development of this T cell lymphoma in these patients was not clear and could not be traced back to the direct effects of transposon integration in a specific gene 190 .”
Allogeneic and other innovative chimeric antigen receptor platforms
Jallouk, A. P., Sengsayadeth, S. M., Savani, B. N., Dholaria, B., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.121404 · Cited by 8
Nitulescu, A., Du, W., Glaser, V., Kath, J., Aird, E., Cullot, G., Greensmith, R., Mikkelsen, N. S., Stein, M., Bak, R., et al. (2024) · bioRxiv · doi:10.1016/j.omtn.2025.102568 · Cited by 5
“4,6 Furthermore, while randomly integrating vectors depend on exogenous promoter-driven transgene expression, gene editing can harness endogenous gene regulation to enhance product potency.”
Калиниченко, С. В., RAMADAN, L., Kruglova, N. A., Balagurov, K., Игоревна, Л. М., Mazurov, D. V., & Shepelev, M. V. (2024) · Biology · doi:10.3390/biology13090675 · Cited by 5
Goto, A., Moriya, Y., Nakayama, M., Iwasaki, S., & Yamamoto, S. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101003 · Cited by 5
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
CAR-T cell therapy: A therapeutic strategy for cancer treatment
Sharif, S., Sharma, U., & Yadav, A. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152430 · Cited by 4
HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression?
Li, Y., Xiao, Q., Yu, F., & Zhang, F. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00104-25 · Cited by 4
Wang, S.-S., Zhang, P.-J., Sun, Y., Fang, Y., Wang, P., Shao, M.-Q., Zhang, N.-N., Shi, S.-S., Chen, X., Gao, H.-X., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf935 · Cited by 4
“Early transposon systems, such as Sleeping Beauty ( SB ) and PiggyBac ( PB ), have demonstrated promising outcomes in preclinical trials, especially in CAR-T gene therapy [ 6 , 7 ].”
Zhou, J.-H., & Kelemen, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178388 · Cited by 4
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy
Maurer, K., Weir, J. A., Nagler, A., Haradhvala, N., Bharadwaj, H., Shapiro, J., Alakwe, S., Kumar, V., Waller, B. F., McDonough, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62709-7 · Cited by 4
“The majority of these do not appear to result from malignant transformation from CAR-T insertional mutagenesis 7,9,10 .”
Maurer, K., & Jacobson, C. (2025) · Leukemia and Lymphoma · doi:10.1080/10428194.2025.2460043 · Cited by 4
“…of the malignant cells multiple chromosomal abnormalities including copy number gains and loss of chromosomes, although insertion of the trans-gene into known oncogenes was not observed [39]. these data have raised concern about the clinical utility of transposon-mediated generation of cAR-t cells.”
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 3
“Some groups have been driving their efforts to develop non-viral CAR T cells, including those based on the PiggyBac transposon [67,71], mRNA delivery through nanocar-riers [72–74], electroporation ex vivo [75–77], or in vivo using LNPs [78].”
CAR T Therapies: Game Changer or Culprit in Cancer Treatment?
Afzal, A., & Khawar, M. (2024) · Albus Scientia · doi:10.56512/as.2024.1.e240305 · Cited by 4
“These include retroviral activation of JAK kinase3 and exceptionally high insertion copy numbers associated with certain methodologies employed in CAR gene delivery, such as the transposon method (Banerjee et al., 2024; Heinrich et al., 2013; Micklethwaite et al., 2021).”
MethodAdoptive cellular therapy after hematopoietic stem cell transplantation
Vittayawacharin, P., Kongtim, P., Chu, Y., June, C. H., Bollard, C. M., & Ciurea, S. O. (2024) · American Journal of Hematology · doi:10.1002/ajh.27204 · Cited by 5
“68 Several other studies have shown safety and efficacy of CAR T-cell therapy post-allogeneic HSCT 69 – 74 (Table 1).”
BackgroundT Cell Receptor Pathway Mutations in Mature T Cell Lymphomas
Zhang, Y., Cheng, K., & Choi, J. (2023) · Journal of Immunology · doi:10.4049/jimmunol.2200682 · Cited by 4
Rajput, A., Sajjad, S. A., Kumar, A., & Singh, K. (2025) · Cureus · doi:10.7759/cureus.81930 · Cited by 3
A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy
Shi, W.-P. J., & Wang, H.-Y. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026021166 · Cited by 2
“47,49 The integration of the CAR transgene was detected in most (73% [8/11]) cases, and many critical genes (tumor suppressors and oncogenes), including but not limited to ARID1A , TP53 , KPNA4 , and TFCP2 , were involved.”
The evolving role of cytokines for CAR-T cell manufacturing and beyond
Guaza-Lasheras, M., Nimmerfroh, J., Schwarz, D., de Gruijl, T. D., Hartmann, J., Klein, C., Laubli, H. P., Lotem, M., Mittelstaet, J., Paget, C., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01703-w · Cited by 3
My, B., Lia, A., Rizzo, L., Maiorano, G., Galeone, A., Palamà, I. E., & Gigli, G. (2026) · iScience · doi:10.1016/j.isci.2026.115422 · Cited by 2
“86,89 Emerging systems such as TcBuster continue to be optimized for high efficiency multicistronic engineering, expanding the toolbox beyond Sleeping Beauty/piggyBac.”
Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies
Ogusuku, I. E. Y., Knelangen, N., Engels, B., Subklewe, M. S., & Lock, D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.006 · Cited by 1
“Nonetheless, recent reports of rare malignant transformation following CAR T cell therapy have heightened concerns about genotoxicity, 231,232 suggesting that strategies relying on non-genetic modifications to improve CAR T cell fitness may ultimately prove more competitive than extensive multiplex…”
Exploration of the potential of genomic editing in the treatment of congenital adrenal hyperplasia
Graves, L. E., Christina, S., Mullany, K., Alexander, I. E., & Falhammar, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1719376 · Cited by 2
Ghorashian, S., Sanderson, R., Lee, J., Black, A., O'Reilly, M., Marks, D., Snowden, J., Richardson, D., & Olavarría, E. (2025) · British Journal of Haematology · doi:10.1111/bjh.70247 · Cited by 2
Multiplex engineering and multifunction T cells for precise and effective immunotherapies
Jafarzadeh, L., Smaani, A., & Delisle, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680410 · Cited by 3
A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune Cells
Skeate, J. G., Slipek, N. J., Lahr, W. S., Roy, S., Wick, B., Stelljes, E. M., Gilkey, A. K., Thenge, P., Diers, M. D., Kar, B., et al. (2025) · bioRxiv · doi:10.1101/2025.07.11.664404 · Cited by 2
“First generation CAR T therapies have seen tremendous success in the clinic against hematologic malignancies (reviewed in 43 ); however, therapeutic cell engineering with randomly integrating vectors poses potential risks 44,45 .”
Šmilauerová, K., Štach, M., Mucha, M., Vaníková, Š., Rychlá, J., & Otáhal, P. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf022 · Cited by 2
“Similarly, the genotoxicity of piggyBac transposon was also reported [39, 40].”
Libertini, S., Jadlowsky, J. K., Lanz, T. A., Mihalcik, L., & Pizzurro, D. M. (2024) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22633 · Cited by 2
“Although the pathogenic mechanism remains undefined, the investigators postulate that the malignant transformation is likely a result of multiple genetic alterations (Bishop et al., 2021; Micklethwaite et al., 2021).”
Sheedy, A. M., Burduli, N., Prakash, A., Gurney, M., Hanley, S., Prendeville, H., Sarkar, S., O'Dwyer, J., O'Dwyer, M., & Dolan, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34976 · Cited by 2
“While there have been some recent concerns raised about the safety of transposon systems, Sleeping Beauty has an almost completely random integration pattern, which may offer increased safety in patients over other transposon systems [40 – 43].”
BackgroundPutting together the pieces: CAR into CD3ζ locus.
Casucci, M. (2024) · Blood · doi:10.1182/blood.2024024491 · Cited by 2
Cecchi, C. R., Alsing, S., de Jesus, G. P. P., Zacarias, E. A., Kjær, L., Clement, M., Kumagai-Braesch, M., Corydon, T., Bartolini, P., Peroni, C. N., et al. (2023) · Tissue & Cell · doi:10.1016/j.tice.2023.102095 · Cited by 2
Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
Martín, F., Schambach, A., & Maccalli, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1119363 · Cited by 2
Chen, Y., Hua, W., Hsu, J. C., Chang, P. S., Wen, K. K., Huang, Y.-W., Tsai, J.-C., Kao, Y.-H., Wu, P.-H., Wang, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.03.490469 · Cited by 2
“A detailed mechanistic study on the case reveals a high number of piggyBac integrants, but none were inserted to or near typical oncogenes(44).”
BackgroundPicanço-Castro, V., Bonamino, M., Ramos, R., Guerino-Cunha, R., Oliveira, T. G., & Rego, E. (2021) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2021.09.008 · Cited by 2
“Although the integration profile of transposon can be considered biologically safe, recently two patients developed malignant lymphoma after a treatment with CAR-T cells anti CD19 using a PB vector.(9) In addition, they are easier to produce on a large scale.”
BackgroundRamos, R., Picanço-Castro, V., Oliveira, T. G., Mendrone, A., de Santis, G. C., Bonamino, M., & Rocha, V. (2021) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2021.09.007 · Cited by 2
In vivo CAR T cells on the highway: a roadmap for the next decade
Barden, M., Harrer, D. C., & Abken, H. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2722287 · Cited by 1
“The approach, however, has led to T cell lymphomas in some patients [49], which may require other transposon elements like Sleeping Beauty for integration.”
Andreotti, I. A. D. A., Griep, G., Patino-Narino, E., Batista-Silva, L. R., Gongora-Rubio, M., Bonamino, M., & Balbino, T. A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08388-4 · Cited by 1
“Transposons, despite their scalability and lower cost, still rely on semi-random genomic integration, raising concerns of insertional mutagenesis and potential long-term genotoxicity [36, 39, 44].”
Dong, R., Zhang, Y.-X., Yuan, G., Yue, X.-Y., Ding, Y., Zeng, X., & Xiao, H.-W. (2026) · Cancer Medicine · doi:10.1002/cam4.71918 · Cited by 1
“Moreover, transposon-based approaches (e.g., Sleeping Beauty , Tc Buster ), which are applied in CAR-γδ T cell preparation [30], have been reported to induce malignant transformation risks [31].”
Liu, X., Gao, H., & Yu, J. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag007
Mammone, R. M., Willis, E., Ruivo, P., Finesso, G., Cox, A., Assenmacher, C., Radaelli, E., Piersigilli, A., & Miranda, I. C. (2026) · Veterinary Pathology-Supplement · doi:10.1177/03009858251409216 · Cited by 1
Strategies to eliminate native T cell receptors for adoptive T cell therapies
Flumens, D., Campillo-Davó, D., Oers, F. V., Shaw, P. A. G., & Lion, E. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.017 · Cited by 1
“109 There are several ways to initiate RNAi (Figure 1), which differ based on their entry point in the RNAi pathway (Table 1).”
Osborne, M., & Maher, J. F. (2025) · Biology · doi:10.3390/biology14121790 · Cited by 1
“Despite showing a favourable safety profile in these trials [66], piggyBAC has been linked to the onset of ‘donor-derived T cell lymphoma’ in two CAR-T recipients, a finding attributed to manufacturing rather than vector-related issues [139].”
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
Hamilton, M., & Alizadeh, A. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.09.002 · Cited by 1
Park, H., Simmonds, M. J., Chevassut, T. J. T., & Morgan, R. G. (2024) · Gene Reports · doi:10.1016/j.genrep.2024.101979
Empowering virus-free CAR immune cell therapies.
Bexte, T., & Ullrich, E. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.023 · Cited by 1
Involvement of Diverse Populations in Transfusion Medicine Research
Miller, Y. M., Bakhtary, S., Chou, S. T., Hailu, B., Reik, R. A., Richard, R. A. H., Spencer, B. R., Witherspoon, R., & Delaney, M. (2023) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2023.150766 · Cited by 1
Safety of genetically modified T cells.
Maus, M. V. (2022) · Blood · doi:10.1182/blood.2022016334 · Cited by 1
Saultz, J. N., & Maziarz, R. (2021) · i Medicina · doi:10.1016/j.medj.2021.07.002 · Cited by 1
Clonal hematopoiesis and cytopenias following CAR19 therapy.
Hamilton, M., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B., Alig, S., Good, Z., Schroers-Martin, J. G., Tamaresis, J., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02795-5
Deedit, N., Suppipat, K., Tawinwung, S., Nakazawa, Y., Hirankarn, N., & Chinsuwan, T. (2026) · bioRxiv · doi:10.64898/2026.10.16.758153
Beyond Viruses: Transposons and CRISPR-Programmable Nonviral Systems for Genome Engineering.
Singh, S., Panchal, O., & Ivics, Z. (2026) · Human Gene Therapy · doi:10.1177/10430342261493722
Suvannasankha, A., Omofuma, O. O., li, M., Phelan, M., Breskin, A., Shao, P., Hearnden, C., Shariff, S., Mukherjee, N., Mohamed, H., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.10.035
T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?
Stella, F., Fraietta, J., Schuster, S., & Ruella, M. (2026) · Haematologica · doi:10.3324/haematol.2026.301592
“…lymphomas reported in the Australian CARTELL trial of donor-derived piggyBac-modified CD19 CAR T cells, one presenting as a retroperitoneal CD4-positive CAR T-cell lymphoma and the second detected as an asymptomatic thoracic para-aortic/mediastinal CAR T-cell tumor during post-trial screening 53 .”
CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences
Bach, D., & Nguyen, T. U. O. N. G. (2026) · Human Gene Therapy · doi:10.1177/10430342261467645
Rewiring cellular immunotherapy: From CAR evolution to circuit innovations across diseases
Chen, J., Cui, Y., Du, K., Liu, J., Xie, J., Wang, S., & Yang, Z. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108980
The emerging roles of alternative splicing in modulating tumor immune responses and immunotherapies
He, X., Zhao, D., Zhou, Y., Jiang, Y., Dong, Z., & Liu, K. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01792-9
Genetically Unmodified Cells for Drug Delivery and Therapy
Zhang, B., Chen, Y., Zhu, C., Qiu, Q., Gu, Z., & Li, H. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00071
Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring
Anelli, L., Cumbo, C., Minervini, A., Zagaria, A., Coccaro, N., Tarantini, F., Tota, G., Conserva, M. R., Redavid, I., Minervini, C. F., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.06.041
Soluble-Antigen-Based PET/MR for the Specific Detection of BCMA CAR+ T-Cell Lymphoma.
Zhou, W., Meng, Y., Yan, Y., Tang, L.-J., Yan, J.-J., Pan, D., Chen, C.-Y., Xu, Y.-P., Wang, L.-Z., Wang, X.-Y., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00097
Park, J. J., Avigan, Z. M., Dong, M. B., Nguyen, C. V., Guitart, J., Kotecha, R., Perica, K., Parekh, S., & Aleman, A. (2026) · Blood neoplasia · doi:10.1016/j.bneo.2026.100244
Zhang, C., Liu, H.-Z., Sangani, H., Jin, D., & Hsu, Y. (2026) · Journal of Immunological Research · doi:10.1155/jimr/9452254
“Previously, there have been reports that in patients receiving CD19 CAR-T, excessive CAR expression led to changes in gene copy numbers and insertions into the BACH2 and FYN genes [27], and among 10 patients in the trial, two developed CAR T tumors, resulting in the death of one individual.”
Zweitmalignom nach CD19-CAR-T-Zell-Therapie
Rudek, L. S., & Alakus, H. (2025) · Die Onkologie · doi:10.1007/s00761-025-01696-2
Identification of clonally expanded γδ T‐cell populations during CAR‐T cell therapy
Safavi, A., Samir, J., Singh, M., Bonomi, M., Louie, R. H. Y., Micklethwaite, K. P., & Luciani, F. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12834 · Cited by 1
“Patients P2 and P8 developed CAR-T cell induced lymphoma at 3.2-and 11.5-months following therapy, respectively 15,16 (Table 1).”
InfluentialSelf-citationTanaka, M., Iwamoto, Y., Wang, B., Imai, E., Yoshida, M., Iriguchi, S., & Kaneko, S. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.03.002
“Although the therapy demonstrated high ef fi cacy, with reported remission in all 10 treated patients, two patients developed CAR-Tcell-derived T-cell lymphoma [36].”
MethodAn optimized polymeric delivery system for piggyBac transposition
Sundaram, D. N. M., C., R., Fu, W., & Uludağ, H. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28665
Metadata
- Authors
- Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., Louie, R. H. Y., Cai, C., Foox, J., MacKay, M., Sedlazeck, F. J., Blombery, P., Mason, C. E., Luciani, F., Gottlieb, D. J., & Blyth, E.
- Affiliations
- The University of Sydney (AU)
- Westmead Institute for Medical Research (AU)
- UNSW Sydney (AU)
- Weill Cornell Medicine (US)
- Baylor University (US)
- The Royal Melbourne Hospital (AU)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-10-21
- Volume
- 138
- Issue
- 16
- Pages
- 1391-1405
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC8532197
- OpenAlex
- W3163947612
- Cited by
- 226
- References
- 0
- Citations by year
- 2026: 32 · 2025: 54 · 2024: 63 · 2023: 30 · 2022: 33 · 2021: 14
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA249054, P01CA214274)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- piggyBac transposon, CD19 chimeric antigen receptor, retroperitoneal lymphoma, para-aortic lymph nodes, B-cell malignancies, transgene copy number, gene expression profiling, CAR T cell safety
- MeSH terms
- Aged, DNA Transposable Elements, Humans, Lymphoma, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Leukemia, B-Cell, Gene Expression Regulation, Neoplastic, Immunotherapy, Adoptive, Lymphoma, B-Cell, Clinical Trials, Phase I as Topic, Gene Transfer Techniques, Transgenes, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review